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ABSTRACT
Somatic mutations in the ARID1A tumor-suppressor gene have been frequently 
identified in ovarian clear cell carcinoma (CCC) cases. BAF250a encoded by ARID1A 
is a member of the SWI/SNF complex, but the expression and mutation status 
of other SWI/SNF subunits have not been explored. The current study aimed to 
elucidate the biological and clinical significance of the SWI/SNF complex subunits, 
by assessing the expression and mutation status of SWI/SNF subunits, and distinct 
genomic aberrations associated with their expression. Of 82 CCC specimens, 38 
samples presented no BAF250a expression, and 50 samples exhibited the loss of at 
least one subunit of the SWI/SNF complex. Cases which lack at least one SWI/SNF 
complex component exhibited significantly more advanced stages, faster growth and 
stronger nuclear atypia compared with SWI/SNF-positive samples (p<0.05). Although 
BAF250a expression is not related to poor prognosis, the group presenting the loss 
of at least one SWI/SNF complex subunit exhibited significantly shorter overall and 
progression-free survivals (p<0.05). A multivariate analysis suggested that the 
expression status of the SWI/SNF complex serves as an independent prognostic factor 
(p<0.005). The cases positive for all SWI/SNF subunits demonstrated significantly 
greater DNA copy number alterations, such as amplification at chromosomes 8q.24.3 
and 20q.13.2-20q.13.33 (including ZNF217) and deletion at chromosomes 13q12.11-
13q14.3 (including RB1), 17p13.2-17p13.1 (including TP53) and 19p13.2-19p13.12. 
In conclusion, the CCCs exhibiting the loss of one or multiple SWI/SNF complex 
subunits demonstrated aggressive behaviors and poor prognosis, whereas the CCCs 
with positive expression for all SWI/SNF components presented more copy number 
alterations and a favorable prognosis.
INTRODUCTION
Ovarian cancer is the most devastating gynecological 
malignancy in the world and is a heterogeneous disease 
with distinct clinicopathological and molecular features 
[1, 2]. The pathological classification of epithelial ovarian 
cancers includes four major histological subtypes based 
entirely on tumor cell morphological criteria: serous 
carcinoma (SC), mucinous carcinoma (MC), endometrioid 
carcinoma (EC) and clear cell carcinoma (CCC). Of these, 
CCC is one of the most aggressive types because unlike 
high-grade SC, it is refractory to conventional cytotoxic 
chemotherapeutic agents [3]. Recent genome-wide studies 
in ovarian CCC have identified somatic mutations in 
Oncotarget2www.impactjournals.com/oncotarget
AT-rich interactive domain 1A (ARID1A) in 46-57% of 
ovarian CCC cases [4, 5] and also identified unique DNA 
methylation profiles, characterized by hypomethylation of 
the hepatocyte nuclear factor-1-beta (HNF1B) pathway 
and hypermethylation of the estrogen receptor alpha 
(ERα) pathway [6]. BAF250a encoded by ARID1A is a 
member of the SWItch/Sucrose Non-Fermentable (SWI/
SNF) chromatin remodeling complex, which comprises 
polymorphic assemblies of at least 14 subunits encoded by 
28 genes, generating an extensive diversity of complexes 
with specialized functions in specific tissues [7-10]. 
Although several subunits of the SWI/SNF complex have 
been reported to possess tumor-suppressive functions in 
the malignancies of several organs [7-9], the expression 
and mutation status of SWI/SNF complex subunits, 
with the exception of BAF250a, have yet to be explored 
in ovarian CCC. The impact of BAF250a on clinical 
prognosis is controversial [11, 12]. Furthermore, the 
biological and functional roles of the SWI/SNF complex 
in ovarian CCC have yet to be elucidated. In this study, the 
expression of SWI/SNF complex subunits and BAF250a 
was assessed to explore the biological and clinical 
significance of these proteins in ovarian CCC.
RESULTS
Expression status of the SWI/SNF complex in 
different histological subtypes of ovarian cancer
Representative immunohistochemistry results for 
nine SWI/SNF complex subunits (BAF250a, BAF250B 
encoded by ARID1B, BRM encoded by SMARCA2, 
BRG1 encoded by SMARCA4, BAF155 encoded by 
SMARCC1, BAF170 encoded by SMARCC2, SNF5 
encoded by SMARCB1, BCL11A and BAF180 encoded 
by PBRM1) are shown in Supplementary Figure S1. The 
expression status of each SWI/SNF complex subunit is 
shown in Figure 1-a, and the frequency of loss of each 
subunit is summarized in Supplementary Figure S2 and 
Supplementary Table S1. The most frequently lost subunit 
of the SWI/SNF complex was BAF250a (41/152, 27.0%). 
Interestingly, BAF250a was lost in CCC (38/82, 46.3%) 
and, to a lesser extent, in EC (3/28, 10.7%), whereas 
none of the SC or MC cases showed loss of BAF250a 
expression (p<0.0001, Supplementary Figure S2-a and 
Supplementary Table S1).
Conversely, the BAF250a complementary subunit, 
BAF250B, continued to be expressed in all ovarian cancer 
cases with the exception of two EC and two MC cases, 
indicating that this subunit is one of the less frequently lost 
subunits. The other frequently lost subunits were SNF5 
and BCL11A, which were lost in four and two cases, 
respectively (Figure 1, Supplementary Figures S2-g, S2-h 
and S2-i, and Supplementary Table S1). BAF170 exhibited 
positive expression in all CCC cases, whereas 11.5% of 
the non-CCC samples exhibited no BAF170 expression, 
indicating a statistically significant difference (p<0.0088, 
Supplementary Figure S2-d and Supplementary Table S1).
Distinct molecular characteristics of different 
histological subtypes of ovarian cancer
The expression of six molecules related to tumor 
development (HNF1B, ERα, P53, pAKT, pMAPK and 
Ki-67) was analyzed through immunohistochemistry, as 
shown in Supplementary Figure S3, and the expression 
status of each is summarized in Figure 1-b and 
Supplementary Figure S4.
A significantly larger proportion of the 67 CCC 
cases (82%) was positive for HNF1B immunostaining, 
whereas the other cancer types with the exception of four 
MC cases were all negative for HNF1B (p<0.0001, Figure 
1-b and Supplementary Figure S4-a). ERα expression was 
lost in all CCC cases with the exception of one, whereas 
ERα continued to be expressed in 75% of EC (21/28), 
50% of SC and 17% of MC cases (p<0.0001, Figure 
1-b and Supplementary Figure S4-b). P53 accumulated 
(Immuno-Reactive Score, IRS≥150) in 50% of SC, 22% 
of EC and 18% of MC cases, whereas out of the 82 tested 
CCC cases, only four cases had an elevated IRS for P53 
(p<0.0001, Figure 1-b and Supplementary Figure S4-c). 
The highest percentage of AKT phosphorylation, denoting 
PIK3CA/AKT/mTOR pathway activation, was observed 
in CCC (61%). pAKT expression in EC reached 57% 
positivity, and pAKT expression in both CCC and EC 
was significantly higher than that in SC (40%) and MC 
(22%) (p<0.0001, Figure 1-b and Supplementary Figure 
S4-d). pMAPK expression in the four subtypes was almost 
within the same 40% range (p=0.9035, Figure 1-b and 
Supplementary Figure S4-e).
High proliferation indices (≥25%) were detected in 
62.2%, 60.7%, 70% and 72.7% of CCC, EC, SC and MC 
cases, respectively. The comparison of the proliferation 
index values among the different types revealed that CCC 
presents significantly slower proliferation than the other 
three subtypes (p=0.0116, Supplementary Figure S4-f).
Expression of SWI/SNF complex subunits in 
CCC
The most frequently lost subunit in CCC was 
BAF250a (38/82, 46.3%), followed by BRM (13/82, 
15.9%) and BRG1 (9/82, 11%). Few cases showed 
negative reactions with BAF155, BAF180, SNF5 and 
BCL11A, whereas BAF250Band BAF170 appeared to 
be positively stained in all CCC cases (Figure 1-a). Of 
the 82 CCC cases, 50 samples (61.0%) exhibited the loss 
of at least one SWI/SNF complex subunit. Thirty-one 
cases (37.8%) lost immunoreactivity for one subunit only, 
whereas 19 cases (23.2%) lacked at least two subunits. Of 
the 19 cases that showed a loss of expression of multiple 
subunits, 15 cases demonstrated the loss of BAF250a 
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together with either BRM or BRG1 (Figure 1-a). The two 
cases that lacked SNF5 also presented a loss of expression 
of BRM, whereas the two cases in which BCL11A was 
lost did not lack any other SWI/SNF subunits.
Effect of the loss of SWI/SNF complex subunits 
on CCC
Whether CCC cases in which SWI/SNF complex 
expression was lost presented certain clinical, biological, 
pathological or molecular features that may distinguish 
these cases from CCC cases in which SWI/SNF expression 
is preserved was then investigated.
First, the clinical backgrounds of the cases were 
assessed. Although there is no association between 
SWI/SNF complex status and age, tumor size, the 
presence of endometriosis or body mass index, cases 
in which SWI/SNF complex expression was lost were 
at a significantly more advanced stage compared with 
cases demonstrating positive expression of all SWI/
SNF complex subunits (p=0.0094, Table 1). Second, the 
comparison of the expression status of HNF1B, ERα, 
P53, pAKT and pMAPK with SWI/SNF subunit staining 
did not reveal any significant variations between the 
cases with positive SWI/SNF expression and cases that 
lacked at least one SWI/SNF component (Supplementary 
Figure 1: Expression heatmaps. a. Expression of nine subunits belonging to the SWI/SNF complex. The color bar represents the 
number of subunits that demonstrate a loss of expression. Dark blue indicates that the sample lacks more than two subunits. Blue indicates 
that the sample is negative for two subunits. Light blue indicates that the sample is negative for one subunit. The lightest blue indicates 
that the sample expresses all subunits. b. Expression of six molecules that represent biological features. The red columns represent positive 
expression, whereas the green columns represent negative expression.
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Figures S5-a to S5-e). Third, the influence of the 
expression of this complex on proliferation was assessed. 
Cases lacking at least one SWI/SNF component, as well 
as BAF250a, proliferated more rapidly than positive 
cases, as determined by comparing their Ki-67 indices 
(p<0.0001, Figure 2-a and Supplementary Figure S5-f). 
In addition, cases lacking multiple subunits presented a 
significantly higher proliferation index than the positive 
cases (p<0.0001) and the cases lacking a single subunit 
(p=0.0067), suggesting that the loss of multiple subunits 
exerted a cumulative effect. Cases presenting the loss of 
core subunits (BAF250a, BAF250B, BRG1 and BRM) 
showed significantly higher Ki-67 indices compared with 
the cases with all core subunits (p<0.0001, Supplementary 
Figure S5-g). Cases lacking non-core subunits (BAF155, 
BAF170, BAF180, SNF5 and BCL11A) exhibited higher 
Ki-67 indices than those with all subunits, but this 
difference was not significant (p=0.0700).
The morphology was then evaluated. Because CCC 
presents three main architectural patterns, specifically 
papillary, tubulocystic and solid (Supplementary 
Figure S6), the architectural patterns of the cases were 
assessed according to the SWI/SNF complex status. 
The results showed that the architectural patterns varied 
significantly with respect to changes in SWI/SNF 
immunoreactivity (p=0.0007, Figure 2-b). The papillary 
pattern was more prevalent in cases lacking a single 
subunit, whereas the solid pattern was more common in 
SWI/SNF-positive cases. Cases lacking multiple subunits 
could show any of the different patterns, although slightly 
more cases exhibited the papillary pattern. Because 
CCC cells frequently exhibit nuclear atypia, the cancer 
cell nuclei were assessed based on the SWI/SNF status 
(Supplementary Results). The nuclei of the cells in the 
SWI/SNF-positive group were found to be more rounded 
and symmetrical, with no beading and no breaks in the 
nuclear membrane (Supplementary Figure S7-l), whereas 
elongation, beading and knobbing of the nuclear surface, 
along with breaks in the nuclear membrane, were observed 
in cases lacking at least one SWI/SNF component 
(Supplementary Figure S7-m).
A microarray analysis identified 58 probes that were 
overexpressed in cases lacking at least one SWI/SNF 
component relative to the positive group (Supplementary 
Table S2). A categorical analysis using DAVID 
produced 37 terms that were significantly enriched in 
the cases lacking at least one SWI/SNF complex subunit 
(Supplementary Table S3). Fourteen of the 37 terms were 
associated with the cell cycle and proliferation.
These results suggest that the loss of SWI/SNF 
complex expression contributes to proliferation and 
nuclear atypia.
The SWI/SNF complex status in ovarian CCC is 
an independent prognostic factor
First, 82 CCC samples at Kyoto University were 
used to produce Kaplan-Meier curves. The prognoses 
of the BAF250a-negative CCC cases in terms of overall 
survival were not different compared with that of 
the BAF250a-positive cases (p=0.1053, Figure 3-a). 
However, cases lacking at least one SWI/SNF complex 
subunit presented significantly poorer prognosis compared 
with cases that were positive for all subunits (p=0.0003, 
Figure 3-b). Furthermore, when divided into three groups, 
denoted “specifically positive for all SWI/SNF complex 
subunits”, “negative for one subunit” and “negative for 
multiple subunits”, the former group presented the most 
Table 1: The clinical backgrounds among SWI/SNF complex status in CCC
SWI/SNF positive 
expression
Loss of expression of 
one subunit




Age (median, in years) 51.10 51.75 54.10 0.48541
FIGO Stage
Stage I 28 19 6
**0.00942
Stage II 2 2 2
Stage III 1 6 8
Stage IV 2 3 3
Maximum Tumor diameter 
(median, in cm) 11 12 12 0.4158
1
Endometriosis 30/33 (90.91%) 27/30 (90%) 17/19 (89.47%) 0.98441
BMI (median) 19.58 21.14 21.88 0.22462
1 P values were calculated using Kruskal Wallis test
2 P values were calculated using Chi-square test
** P value <0.005
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Figure 2: Distinctive proliferation and morphological features based on SWI/SNF complex expression status. a. Cases 
lacking multiple subunits had the highest Ki-67 proliferation indices. b. Loss of SWI/SNF subunit expression in ovarian clear cell carcinoma 
tended to result in papillary architectural patterns. c-g. The cases lacking at least one SWI/SNF component had smaller and flatter nuclei 
with irregular outlines. The nuclei in the SWI/SNF-positive group are more rounded and symmetrical and showed no beading in the nuclear 
membrane h. whereas more elongation, beading and knobbing of the nuclear outline, as well as breaks in the nuclear membrane, were 
observed in cases lacking at least one subunit i.
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Figure 3: Kaplan-Meier curves for overall (a-d) and progression-free survival (e-h) based on BAF250a status and 
SWI/SNF complex expression. The analysis of the samples from Kyoto University revealed that BAF250a expression is not related 
to prognosis in terms of overall (a) and progression-free (e) survival, whereas the loss of SWI/SNF subunit expression is associated with 
poorer prognosis in terms of overall (b) and progression-free (f ) survival. The poor prognosis was more evident with the loss of multiple 
SWI/SNF subunits (overall and progression-free survival, (c) and (g), respectively). The analysis of the validation datasets from Kinki 
University also indicated that increases in the number of SWI/SNF subunits that presented a loss in expression resulted in poorer prognosis 
(overall and progression-free survival, (d) and (h), respectively).
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favorable prognosis, whereas the group lacking multiple 
subunits had the worst prognosis (p<0.0001 for the 
three groups, Figure 3-c). In terms of progression-free 
survival, although the BAF250a-negative cases did not 
demonstrate a significant reduction in survival compared 
with the BAF250a-positive cases (p=0.7689, Figure 3-e), 
cases lacking at least one SWI/SNF complex subunit 
exhibited a significantly poorer prognosis compared 
with cases in which all SWI/SNF complex subunits were 
present (p=0.0079, Figure 3-f). Poor prognosis was more 
evident in cases lacking multiple subunits (p=0.0006 for 
the three groups, p=0.0006 between the cases positive 
for all subunits and the cases lacking multiple subunits, 
p=0.0638 between the cases lacking one subunit and the 
cases lacking multiple subunits; Figure 3-g). The division 
of the group of cases lacking at least one subunit into cases 
lacking core subunits and cases lacking non-core subunits 
revealed that both groups showed significantly poorer 
prognosis in terms of overall and progression-free survival 
compared with the group of cases positive for all subunits 
(Supplementary Figure S8).
Second, to validate these results at Kyoto University, 
another set of 54 CCC samples from Kinki University 
was stained to assess their SWI/SNF complex status. 
Interestingly, similar results were obtained: a loss of 
expression resulted in a worse prognosis in terms of both 
overall and progression-free survival, and this result was 
more marked with the loss of multiple subunits compared 
with the loss of one subunit (p<0.05 for both, Figures 3-d 
and 3-h).
To identify prognostic factors for ovarian CCC, 
univariate and multivariate analyses of the overall and 
progression-free survival rates were performed using the 
combined datasets from Kyoto and Kinki Universities. 
The univariate analysis of overall survival showed that 
the loss of expression of at least one SWI/SNF subunit, 
FIGO staging, residual tumor size and complication with 
thromboembolism were significant prognostic factors 
for CCC survival (p=0.0005, p<0.0001, p<0.0001 and 
p=0.0022, respectively; Table 2). The multivariate 
analyses indicated that the loss of expression of at least 
one SWI/SNF subunit in addition to the FIGO stage was an 
independent prognostic factor associated with poor overall 
survival (p=0.0132 and p=0.0030, respectively; Table 2). 
For progression-free survival, the loss of expression of 
multiple SWI/SNF subunits, FIGO staging, residual 
tumor size and complication with thromboembolism 
were significant prognostic factors (p=0.0038, p<0.0001, 
p<0.0001 and p=0.0008, respectively; Table 3). The FIGO 
stage was identified as an independent prognostic factor 
for progression-free survival (p=0.0001, Table 3). To 
evaluate the impact of the loss of multiple subunits, a Cox 
proportional hazards regression model was implemented 
using the following two groups: the cases lacking no or 
a single SWI/SNF component and the group presenting 
the loss of multiple SWI/SNF complex subunits. The 
loss of multiple SWI/SNF subunits, as well as the FIGO 
stage, were found to be independent prognostic factors 
associated with poor overall survival (p=0.0005 and 
p=0.0042, respectively; Supplementary Table S4) and 
progression-free survival (p=0.0030 and p<0.0001, 
respectively; Supplementary Table S5). These findings 
suggest that the loss of SWI/SNF complex subunits is a 
prognostic factor, and the strength of this factor is more 
evident with the loss of multiple subunits.
Mutational status of the SWI/SNF complex 
subunits and copy number variations in CCC
Exome sequencing was performed to identify single 
nucleotide variants (SNVs) of genes belonging to the SWI/
SNF complex and to evaluate genome-wide copy number 
variations (CNVs) in the expression of SWI/SNF complex 
subunits. SNVs were identified in four genes (ARID1A, 
SMARCD3, ARID1B and BCL11B; Supplementary 
Figure S9). Somatic mutations occurred most frequently 
in ARID1A, with a frequency of 75.0% (12 out of 16). The 
second most frequent SNV was in ARID1B (12.5%, two 
out of 12), followed by BCL11B and SMARCD3 (6.3%, 
one out of 12 for both).
The SNV status was compared with protein 
immunoreactivity in 16 samples that included both tumor 
specimens and normal counterparts (Supplementary 
Figure S10). Nine out of 12 samples that had mutations in 
ARID1A exhibited no BAF250a expression, whereas two 
out of four cases that did not have mutations in ARID1A 
exhibited positive expression for BAF250a (sensitivity = 
75.0% and specificity = 50.0%, Supplementary Table S6). 
Immunohistochemistry analysis showed that two cases 
that possessed mutations in the ARID1B gene expressed 
the BAF250B protein. No SNVs were identified in the 
other seven genes.
To elucidate genomic differences defined by CNVs, 
14 cases that showed positive expression for all SWI/SNF 
complex subunits were compared with 25 samples that 
demonstrated the loss of expression of at least one subunit. 
The positive cases presented increased amplification of 
chromosomes 8q.24.3 and 20q.13.2-20q.13.33 (including 
ZNF217) and increased deletion of chromosomes 
13q12.11-13q14.3 (including RB1), 17p13.2-17p13.1 
(including TP53) and 19p13.2-19p13.12 (Figure 4). 
Therefore, the SWI/SNF-positive group presented more 
frequent chromosomal alterations compared with the cases 
lacking at least one SWI/SNF subunit.
DISCUSSION
The impact on clinical behaviors and the expression 
and mutation status of SWI/SNF complex subunits have 
yet to be explored in ovarian CCC. Loss of BAF250a 
expression was found to be specific to CCC (46.3% of 
CCC specimens) in this study. This result is compatible 
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with those obtained in previous studies, which showed 
that BAF250a expression is lost in 42% of ovarian 
CCC cases [4]. The analysis of the nine SWI/SNF 
subunits revealed that 61% of CCC samples lacked the 
expression of at least one subunit and that 23.2% of CCC 
cases exhibited the loss of multiple SWI/SNF subunits, 
suggesting a cumulative loss of SWI/SNF complex 
expression. However, this study has some limitations. 
One limitation is that other SWI/SNF components, such 
as BAF200 encoded by ARID2, BCL11B, and BRD9, 
were not evaluated. Another is that some variants cannot 
be detected by immunohistochemistry. A comprehensive 
assessment and a knowledge-based analysis are necessary 
to elucidate the expression of the entire SWI/SNF complex 
in ovarian CCC.
Mutations in the ARID1A and TP53 genes are 
mutually exclusive, and BAF250a requires the formation 
of a complex with P53 to inhibit P53-related genes, 
including tumor suppressors, in gynecologic malignancies 
[13]. Our findings showed no relationship between SWI/
SNF complex expression and P53 expression in CCC 
samples. One possible reason is the distinct evaluation 
methods used in our investigation compared with those 
used in a previous study. Specifically, immunoreactivity 
was assessed in this study, whereas Guan et al. evaluated 
the mutation status of ARID1A and TP53 [13]. Another 
reason is the discrepancy between P53 protein expression 
and TP53 gene mutations [14]. Although the Ki-67 index 
indicated a slow growth of ovarian CCC compared with 
the other histological subtypes, the absence of SWI/SNF 
Table 2: Univariate and multivariate analysis of overall survival rate
OS Univariate analysis Multivariate analysis
Variable subsets N HR 95% CI P value HR 95% CI P value
Lower Upper Lower Upper
Age
<55y 75
1.3233 0.7066 2.4785 0.3815
≥55y 61
FIGO stage
I & II 88
6.0998 3.0999 12.0026 ****<0.0001 1.9191 1.2483 2.9502 **0.0030




















5.3290 2.0865 13.6107 ***0.0005 3.3790 1.2903 8.8490 **0.0132
Number of 
negative 





1.3472 0.7233 2.5092 0.3477
Negative 
expression 61






subunits, as well as BAF250a, was significantly correlated 
with advanced stages and proliferation of ovarian CCC, 
supporting the role of the SWI/SNF complex as a tumor-
suppressive complex. The present study also indicated that 
the absence of SWI/SNF complex expression is correlated 
with the architectural papillary pattern and nuclear 
irregularity. Bourgo et al. showed that loss of BRG1 
leads to nuclear malformations [15]. Imbalzano et al. 
demonstrated that BRG1 knockdown induces grooves in 
the nuclear periphery through internal nuclear mechanisms 
[16]. Nuclear atypia, which is often observed in ovarian 
CCC cells, likely results from loss of SWI/SNF complex 
function. However, Bennett et al. reported that grading 
ovarian clear cell carcinomas based on architectural 
patterns and nuclear shape does not provide survival 
differences, indicating that the clinical significance of 
these factors is controversial [17, 18]. In fact, our samples 
did not show that the architectural pattern serves as a 
prognostic factor (data not shown). The impact of the SWI/
SNF status on nuclear atypia requires further investigation 
because the evaluation of nuclear atypia is not definitive.
Katagiri et al. reported that loss of BAF250a 
expression is correlated to shorter progression-free 
survival, whereas Maeda et al. insisted that there are no 
significant differences between BAF250a-positive and 
BAF250a-negative cases [11, 12]. In our study, BAF250a 
expression, as a single factor, did not contribute to overall 
and progression-free survival; however, the expression 
of SWI/SNF complex subunits was an independent 
prognostic factor of ovarian CCC. This phenomenon 
Table 3: Univariate and multivariate analysis of progression-free survival rate
PFS Univariate Analysis Multivariate Analysis
Variable subsets N HR 95% CI P value HR 95% CI P value
Lower Upper Lower Upper
Age
<55y 75
1.1550 0.6399 2.0850 0.6325
≥55y 61
FIGO stage
I & II 88
7.4504 3.8828 14.2962 ****<0.0001 2.2256 1.4802 3.3464 ***0.0001




























0.9241 0.5113 1.6701 0.7938
Negative 
expression 61






became more evident with the loss of multiple subunits, 
suggesting that the function of the SWI/SNF complex, 
as well as that of BAF250a, is cumulative and essential 
for tumor progression in CCC cases. Because the results 
obtained using the CCC samples from Kyoto University 
were validated using ovarian CCC samples from Kinki 
University, these reproducible findings using independent 
datasets indicate that the expression of the entire SWI/SNF 
complex is a useful biomarker for predicting the prognosis 
of ovarian CCC.
Although genome-wide analyses conducted by 
Kadoch et al. identified several mutations in SWI/SNF 
complex subunits. [7], these genes have been identified 
in only a limited number of samples. In the current 
study, 16 CCC samples, which is a limited number of 
samples, were used to identify mutations in SWI/SNF 
complex subunits. Four genes, including two novel 
genes, associated with the SWI/SNF complex were 
found to be mutated in ovarian CCC. ARID1A was the 
most frequently mutated gene in the SWI/SNF complex, 
and its expression was found to be negatively correlated 
with its mutational status. However, the analysis of the 
correlation of ARID1A expression with its mutational 
status in five of the samples introduced discrepancies. 
For these heterozygous cases, Weigand et al. reasoned 
a detectable protein that is produced by some mutations 
and post-transcriptional or post-translational regulation 
or dominant-negative effects of the mutations [4]. Three 
cases investigated in this study that showed positive 
immunoreactivity for BAF250a instead of harboring 
mutations showed unknown amino acid alterations even 
if the sequence exhibited frameshift insertion or deletion 
mutations. For the other subunits, with the exception of 
BAF250a, our findings suggest that the expression is 
not suppressed by mutations, which may be due to the 
limited number of samples used for the comparison of the 
mutational status with protein expression. Thus, additional 
cases should be studied to resolve the discrepancy between 
expression and mutational status. Another reason for this 
discrepancy could be that the expression of SWI/SNF 
subunits is suppressed by microRNA and methylation 
in malignancies of several organs [19-24]. In this study, 
we detected amplification at chromosomes 8q and 20q 
in many CCC samples. Kuo et al. found that the level 
of chromosomal instability in CCC, as defined by the 
extent of DNA copy number alterations, is similar to that 
Figure 4: Copy number alterations according to chromosomal loci. Left) DNA copy number changes are represented as pseudo-
color gradients corresponding to the copy number increase (red boxes) and decrease (blue boxes). Each column represents an individual 
tumor sample. Right) Copy number aberrations for the SWI/SNF-positive cases compared with the negative cases are depicted on Manhattan 
plots. The dark and light blue colors indicate more amplification and deletion in the positive cases compared with the negative cases.
Oncotarget11www.impactjournals.com/oncotarget
observed in low-grade ovarian SC but markedly less than 
that found in high-grade SC, and the most remarkable 
aberration is a gain at chromosome 20q [25]. Rahman et 
al. also reported chromosome 20q locus amplification in 
ovarian CCC [26]. Two previous studies demonstrated the 
gain of chromosomes 1q, 8q, 17q and 20q and the loss 
of chromosomes 8p, 9q and 19p in ovarian CCC [27, 
28]. Our data are compatible with these previous reports. 
The comparison of CNV with the SWI/SNF complex 
status revealed amplifications at chromosomes 8q.24.3 
and 20q.13.2-20q.13.33 and deletions at chromosomes 
13q12.11-13q14.3, 17p13.2-17p13.1 and 19p13.2-
19p13.12 in the cases that retained the expression of all 
subunits compared with the cases that lacked SWI/SNF 
subunits. However, no specific copy number change was 
observed in the group that presented a loss of SWI/SNF 
expression. The chromosome 20q13.2 includes ZNF217, 
which was reported to be a frequently amplified locus 
and related to cell growth and anti-apoptosis in CCC 
[25, 26]. Chromosome 13q14.2 comprises RB1, and 
chromosome 17p13.1 is composed of TP53. The deletion 
of RB1 and TP53 is commonly observed in somatic copy 
number analyses across different types of cancer [29]. 
Positive protein expression of SWI/SNF and copy number 
alterations appear to be inversely correlated. Although the 
mechanism through which an intact SWI/SNF complex 
is associated with copy number alterations has not yet 
been elucidated, a similar phenomenon was observed in a 
different malignancy. ARID5B classified in the SWI/SNF 
complex family is less mutated in the high-copy-number 
subtype of endometrial carcinoma [30]. These findings 
suggest that SWI/SNF-positive cases are characterized by 
genomic instability with frequent copy number aberrations 
[2, 31, 32].
In summary, the absence of at least SWI/
SNF complex subunit as well as BAF250a activates 
proliferation and irregularities in the nuclear shape. The 
loss of SWI/SNF complex subunits is a prognostic factor, 
and this finding is more evident with the loss of multiple 
subunits. BAF250a expression is suppressed by mutations, 
which are most frequently found in this subunit among 
the SWI/SNF subunits. Two subtypes of ovarian CCC 
can be classified based on SWI/SNF complex expression. 
The first subtype includes cases in which the expression 
of SWI/SNF complex subunits is lost and is associated 
with poor prognosis due to aggressive growth. The second 
subtype includes cases that fully express the SWI/SNF 
complex. The genetic background of this subtype involves 
more frequent copy number alterations relative to cases 
lacking at least one subunit. These findings may lead to 
the development of novel diagnostic tools and therapeutic 
strategies based on precision medicine.
MATERIALS AND METHODS
Refer to Supplementary Materials and Methods.
Tissue materials
This study was approved by the Institutional Review 
Board of Kyoto University and Kinki University. One 
hundred and fifty-two epithelial ovarian cancer cases 
comprising 82 CCC, 28 EC, 20 SC and 22 MC cases were 
investigated to determine the expression of nine main 
SWI/SNF complex subunits (BAF250a, BAF250B, BRM, 
BRG1, BAF155, BAF170, SNF5, BCL11A and BAF180). 
Another 54 CCC samples from Kinki University were 
used to validate the clinical significance of the expression 
of these nine SWI/SNF complex subunits. Staining 
for HNF1B, ERα, P53, pAKT, pMAPK and Ki-67 
was also performed. All of the antibodies are listed in 
Supplementary Table S7.
Pathological review
Clear cell carcinomas exhibit three main 
architectural patterns, namely papillary, tubulocystic and 
solid patterns [33, 34]. The tumor pattern is assigned based 
on the predominance of a certain architecture in more than 
50% of all examined sections of the tumor. The nuclear 
shape was analyzed using the integrated morphometry 
package of MetaMorph® Image analyzer (version 6.1, 
Universal Imaging Corp., West Chester, PA, USA).
Evaluation of staining
Protein expression was evaluated by determining the 
Immuno-Reactive Score (IRS) [35], which is obtained by 
multiplying the percentage of positively stained cells by 
the intensity of the reaction. The percentage of positive 
cells ranged from 0% to 100%, and the intensity of the 
reaction was scored a value from 0 to 3 as follows: no 
reaction, 0; weak, 1; moderate, 2; or strong, 3. Therefore, 
the scores ranged from 0 to 300. Scores between 0 and 
49 were classified as negative, whereas scores ≥50 were 
considered to indicate positive expression.
In the analysis of P53 staining, cases with high 
immunoreactivity scores (≥150) were considered to 
suggest a potential gain-of-function mutation of TP53, 
whereas cases with lower scores were considered to 
express wild-type P53 or null mutations based on a 
previously published report [14]. The IRSs were reviewed 
by a gynecologic pathologist who was blinded to the 
patient data.
The Ki-67 labeling index was analyzed using image 
analysis software (ImageJ) [36]. For each case, 10 high-
power field areas (×400) of maximal tumor positivity 
were selected, and each field contained 50-250 nuclei. The 
percentages of positive nuclei were determined [37].
Microarray analysis
A total of 17 ovarian CCC samples, which were 
frozen immediately after surgery and stored at -80 ºC, 
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were used for mRNA expression microarray analysis. 
Microarray analysis was performed using Affymetrix 
Human Genome U133A 2.0 Arrays following standard 
Affymetrix protocols (Affymetrix, Santa Clara, CA, 
USA). Fifty-eight genes were identified as differentially 
expressed between cases lacking at least one SWI/SNF 
component and positive cases if the expression change 
was greater than twofold based on a t-test with a p-value 
less than 0.05. The biological roles of the 58 genes were 
analyzed by categorical analysis (gene ontology terms and 
TRANSFAC, which represents activation of transcription) 
using the web-based Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 
(http://david.abcc.ncifcrf.gov/).
Whole-exome sequencing
The frozen tissue samples of 39 CCC cases and 16 
lymphocyte samples isolated from whole blood of the 
corresponding CCC patients were used for whole-exome 
sequencing analyses. To identify somatic mutations (single 
nucleotide variants), 16 samples were compared with 
their normal counterparts. Thirty-nine CCC cases were 
assessed for copy number variations between SWI/SNF-
positive cases and cases lacking one or more SWI/SNF 
subunits. GISTIC2.0 [38] and the Bioconductor package 
“copynumber” in R [39] were used for the analysis and 
visualization of the copy number variations (CNVs). A 
samroc analysis [40] was performed to evaluate the copy 
numbers between SWI/SNF-positive CCC cases and CCC 
cases lacking one or more subunits.
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